HOOKIPA Pharma (HOOK) announced that it has received notification from Roche (RHHBY) of their decision to terminate the collaboration and licensing agreement for HOOKIPA’s HB-700 program in KRAS mutated cancers. To date, HOOKIPA has met all go-forward criteria under the agreement and remains eligible for a final milestone payment associated with IND submission. Effective April 25, 2024, HOOKIPA will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program. As part of its strategic refocus, HOOKIPA will pause development activities related to HB-300 and most of its preclinical research activities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOOK:
- HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
- Hookipa Pharma appoints WInderlich as Chief Development Officer
- HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
- Hookipa Pharma files to sell 15M shares of common stock for holders
- HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
